BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21323105)

  • 1. Development of nanosuspension formulation for oral delivery of quercetin.
    Sun M; Gao Y; Pei Y; Guo C; Li H; Cao F; Yu A; Zhai G
    J Biomed Nanotechnol; 2010 Aug; 6(4):325-32. PubMed ID: 21323105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
    Nagaraj K; Narendar D; Kishan V
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
    Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
    Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK; Patel MH; Patel K
    Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles.
    Li H; Zhao X; Ma Y; Zhai G; Li L; Lou H
    J Control Release; 2009 Feb; 133(3):238-44. PubMed ID: 18951932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of a chemically stable quercetin formulation using nanosuspension technology.
    Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J
    Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.
    Gao Y; Li Z; Sun M; Li H; Guo C; Cui J; Li A; Cao F; Xi Y; Lou H; Zhai G
    Drug Dev Ind Pharm; 2010 Oct; 36(10):1225-34. PubMed ID: 20545506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
    Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
    Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability.
    Hashem FM; Al-Sawahli MM; Nasr M; Ahmed OA
    Drug Des Devel Ther; 2015; 9():3141-52. PubMed ID: 26150693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
    Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rutin nanosuspension for potential management of osteoporosis: effect of particle size reduction on oral bioavailability,
    Gera S; Pooladanda V; Godugu C; Swamy Challa V; Wankar J; Dodoala S; Sampathi S
    Pharm Dev Technol; 2020 Oct; 25(8):971-988. PubMed ID: 32403972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and in vitro and in vivo evaluation of quercetin-loaded mixed micelles for oral delivery.
    Lu Z; Bu C; Hu W; Zhang H; Liu M; Lu M; Zhai G
    Biosci Biotechnol Biochem; 2018 Feb; 82(2):238-246. PubMed ID: 29327653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preparation of nanosuspension of quercetin with a miniaturized milling method].
    Liu X; Liu J; Pang JY; Shen BD; Shen CY; Lian WQ; Li XF; Yuan HL
    Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2984-2988. PubMed ID: 29139267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
    Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
    Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats.
    Bagad M; Khan ZA
    Int J Nanomedicine; 2015; 10():3921-35. PubMed ID: 26089668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
    Li W; Yang Y; Tian Y; Xu X; Chen Y; Mu L; Zhang Y; Fang L
    Int J Pharm; 2011 Apr; 408(1-2):157-62. PubMed ID: 21295124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity.
    Jain S; Jain AK; Pohekar M; Thanki K
    Free Radic Biol Med; 2013 Dec; 65():117-130. PubMed ID: 23792276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY; Shah DA; Dave RH
    Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
    Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.